NOW AVAILABLE ON DEMAND
Thursday 17thNovember | 08:00 PDT | 11:00 EDT | 16:00 GMT
Tales from the trenches: lessons from industry leaders on how to ensure quality, improve patient access, and reduce the cost of manufacturing.
Are you preparing to advance your therapy into the clinic? Discover how to avoid common pitfalls therapy developers make when manufacturing cell and gene therapies.
In the race to get novel therapies into clinical trials, early-stage biotechs must objectively assess their readiness and make critical decisions about where and how to manufacture.
Join us as a panel of industry experts shed light on where most early stage biotechs go wrong in overestimating their readiness. Encouraging you to take an in-depth look at your product, capabilities, technologies, processes, and team, this panel discussion will prepare you for success as you bring your product from the bench to patients worldwide. You’ll gain coveted insight needed to advance your readiness as you learn what key indicators to look for and how to assess them.
Immediately applicable, these tales from the trenches are guaranteed to save you time and money by revealing what you don’t know until you’ve been through every step of clinical manufacturing.
WHAT TO EXPECT
Part 1: The panel addresses key challenges associated with clinical manufacturing and the common mistakes therapy developers make when faced with external pressures. Topics covered include:
A well-defined product: why it’s so important to define specifications, dosing, QBD, CPP, and more early on
Assessing scalability, repeatability, and GMP readiness of your manufacturing process
Minimizing the chance of error, reducing contamination risk, and speeding up processing time
The criticality of having the right team built prior to manufacturing
Is outsourcing to a CDMO the right move, and are you ready for that partnership?
Part 2: The panel answers audience questions with an interactive Q&A.
This webinar will be produced in partnership with BioCentriq
In this interview Professor Dimitri Kullmann and Dr Gabriele Lignani , of UCL’s Queen Square Institute of Neurology, spoke to Phacilitate’s Anna Osborne about their research developing a gene therapy as a treatment for drug-resistant epilepsy and the promising results they have seen so far.
For this interview, Phacilitate’s Becky-Johnson Kent speaks with Cintia Piccina, CCO of AdaptImmune, about what to expect from her role as a panellist in the session ‘Cell Therapy Commercial Success, Overcoming Pitfalls and What We Have Learned from 2022′, at Advanced Therapies Week 2023.
Biogen, has announced the European Medicines Agency (EMA), has accepted its Marketing Authorization Application (MAA) for the review of torfersen – its investigational drug to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).